Feb-11-21 Upgrade
Piper Sandler
Neutral → Overweight
$20 → $52
Nov-03-20 Downgrade
Piper Sandler
Overweight → Neutral
$12
Oct-02-20 Upgrade
JP Morgan
Neutral → Overweight
$15
Sep-09-20 Initiated
Morgan Stanley
Equal-Weight
$7
Jun-02-20 Resumed
Cantor Fitzgerald
Overweight
$5
Mar-09-20 Resumed
Cantor Fitzgerald
Overweight
$5
Oct-15-19 Upgrade
Piper Jaffray
Neutral → Overweight
$8
Apr-02-19 Downgrade
Stephens
Overweight → Equal-Weight
$4.50 → $8
Oct-19-18 Initiated
Cowen
Outperform
Nov-03-17 Downgrade
First Analysis Sec
Overweight → Equal-Weight
$4
Sep-28-17 Downgrade
CL King
Buy → Neutral
Nov-03-16 Reiterated
Cantor Fitzgerald
Buy
$18 → $15
Jun-27-16 Initiated
CL King
Buy
Apr-15-16 Initiated
First Analysis Sec
Overweight
$11
Feb-04-16 Downgrade
Piper Jaffray
Overweight → Neutral
Jan-04-16 Reiterated
Cantor Fitzgerald
Buy
$11 → $18
Oct-23-15 Upgrade
Piper Jaffray
Neutral → Overweight
Aug-27-15 Initiated
Cantor Fitzgerald
Buy
Feb-04-15 Reiterated
Maxim Group
Buy
$10 → $11
Sep-26-13 Reiterated
Maxim Group
Buy
$4 → $8
Mar-02-21 04:30PM
Feb-26-21 04:04PM
Feb-24-21 08:00AM
Feb-19-21 09:50AM Investor's Business Daily
Feb-18-21 08:01AM
Feb-12-21 12:08AM
Feb-11-21 12:24PM
08:24AM
06:00AM
Feb-10-21 09:31PM
07:41PM
07:30PM
05:15PM
04:24PM
04:02PM
02:30PM
12:26PM
10:28AM
08:45AM
08:44AM
08:41AM
08:00AM
05:20AM
Feb-09-21 10:23AM
09:29AM
Feb-05-21 05:00PM
Feb-02-21 12:24PM
06:12AM
Jan-29-21 04:15PM
Jan-27-21 02:30PM
Jan-26-21 11:05AM
Jan-20-21 11:36AM
Jan-13-21 12:19PM
11:15AM
08:02AM
Jan-12-21 06:26PM
Jan-11-21 07:45AM
Jan-08-21 03:16PM
08:45AM
08:00AM
Jan-07-21 09:13AM
Jan-01-21 01:31AM
Dec-31-20 05:00AM
Dec-24-20 11:10AM
Dec-23-20 07:29PM
08:37AM
Dec-18-20 04:05PM
Dec-16-20 08:00AM
Dec-14-20 08:00AM
Dec-10-20 10:02AM
Dec-09-20 12:04PM
Dec-03-20 12:36PM
12:15PM
Dec-02-20 11:30AM
Nov-11-20 12:21AM
Nov-10-20 04:05PM
Nov-04-20 08:39AM
Nov-03-20 06:15AM
05:19AM
04:02AM
Nov-02-20 06:15PM
04:46PM
04:02PM
02:30PM
Oct-30-20 12:51PM
Oct-26-20 12:31PM
Oct-22-20 08:00AM
Oct-19-20 12:30PM
Oct-15-20 08:00AM
Oct-08-20 11:30AM
Oct-06-20 07:44PM
Oct-05-20 08:00AM
Oct-02-20 03:37PM
12:00PM
Sep-23-20 08:59AM
Sep-22-20 07:13AM
Sep-16-20 11:55AM
Sep-14-20 09:00AM
Sep-09-20 09:44AM
Sep-02-20 11:30AM
Aug-18-20 08:43AM
Aug-12-20 12:51PM
Aug-11-20 11:20PM
04:32PM
Aug-10-20 01:02PM
Aug-07-20 08:30AM
Aug-04-20 08:14AM
06:40AM
02:01AM
Aug-03-20 06:35PM
04:02PM
08:05AM
08:00AM
Aug-02-20 11:08AM
Jul-27-20 12:31PM
Jul-24-20 12:07PM
Jun-23-20 01:21PM
Jun-10-20 08:59AM
Jun-08-20 04:02PM
Jun-05-20 11:31AM
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. The company also provides consumable products, including SMRT cells, as well as various reagent kits designed for specific workflow such as template preparation to convert DNA into SMRTbell double-stranded DNA library formats including molecular biology reagents, such as ligase, buffers and exonucleases. In addition, it provides binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprises reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences has collaboration with Asuragen to develop assays for carrier screening and other applications based on SMRT sequencing technology and AmplideX PCR chemistry; Invitae Corporation focuses on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. has collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hunkapiller Michael Director Feb 26 Option Exercise 6.36 234,246 1,490,207 1,082,651 Mar 02 08:31 PM Hunkapiller Michael Director Feb 26 Sale 31.02 234,246 7,265,866 848,405 Mar 02 08:31 PM Hunkapiller Michael Director Feb 25 Option Exercise 6.40 339,377 2,172,291 1,187,782 Feb 26 08:34 PM Hunkapiller Michael Director Feb 25 Sale 32.33 339,377 10,972,944 848,405 Feb 26 08:34 PM Hunkapiller Michael Director Feb 24 Option Exercise 6.05 266,427 1,613,096 1,114,832 Feb 26 08:34 PM Hunkapiller Michael Director Feb 24 Sale 36.80 266,427 9,805,281 848,405 Feb 26 08:34 PM Hunkapiller Michael Director Feb 23 Option Exercise 5.97 373,321 2,227,849 1,221,726 Feb 24 08:50 PM Hunkapiller Michael Director Feb 23 Sale 34.88 373,321 13,022,317 848,405 Feb 24 08:50 PM Hunkapiller Michael Director Feb 22 Option Exercise 5.53 229,127 1,266,251 1,077,532 Feb 24 08:50 PM Schaefer Eric Chief Accounting Officer Feb 22 Sale 39.20 3,842 150,606 88,474 Feb 24 08:21 PM Hunkapiller Michael Director Feb 22 Sale 39.14 229,127 8,967,407 848,405 Feb 24 08:50 PM ORDONEZ KATHY Director Feb 16 Option Exercise 4.92 185,879 915,243 242,646 Feb 18 09:52 PM ORDONEZ KATHY Director Feb 16 Sale 47.99 220,771 10,595,810 21,875 Feb 18 09:52 PM Botstein David Director Feb 12 Option Exercise 4.42 160,000 706,800 160,000 Feb 17 09:15 PM LIVINGSTON RANDALL S Director Feb 12 Option Exercise 4.36 67,500 294,400 67,500 Feb 17 09:17 PM Shapiro Lucy Director Feb 12 Sale 50.40 101,666 5,123,966 0 Feb 17 09:19 PM LIVINGSTON RANDALL S Director Feb 12 Sale 48.07 67,500 3,244,455 0 Feb 17 09:17 PM Botstein David Director Feb 12 Sale 49.62 160,000 7,939,764 0 Feb 17 09:15 PM Hunkapiller Michael Director Jan 25 Option Exercise 6.14 125,406 769,993 973,811 Jan 27 05:07 PM Hunkapiller Michael Director Jan 25 Sale 36.34 125,406 4,556,901 848,405 Jan 27 05:07 PM Hunkapiller Michael Director Jan 22 Option Exercise 6.14 150,857 926,262 999,262 Jan 22 09:49 PM Hunkapiller Michael Director Jan 22 Sale 36.77 150,857 5,547,490 848,405 Jan 22 09:49 PM Hunkapiller Michael Director Jan 21 Option Exercise 3.31 208,711 691,411 1,106,926 Jan 22 09:49 PM Hunkapiller Michael Director Jan 21 Sale 36.58 258,521 9,457,071 848,405 Jan 22 09:49 PM Hunkapiller Michael Director Jan 20 Option Exercise 2.27 215,026 488,109 1,113,241 Jan 22 09:49 PM Hunkapiller Michael Director Jan 20 Sale 39.19 215,026 8,426,269 898,215 Jan 22 09:49 PM Hunkapiller Michael Director Dec 22 Option Exercise 3.01 364,451 1,096,998 1,262,666 Dec 23 06:34 PM Hunkapiller Michael Director Dec 22 Sale 25.62 364,451 9,335,716 898,215 Dec 23 06:34 PM Hunkapiller Michael Director Dec 21 Option Exercise 2.88 335,549 965,877 1,233,764 Dec 23 06:34 PM Hunkapiller Michael Director Dec 21 Sale 23.00 335,549 7,718,327 898,215 Dec 23 06:34 PM Hunkapiller Michael Director Nov 24 Sale 14.39 1,492 21,462 0 Nov 25 04:46 PM Hunkapiller Michael Director Nov 23 Sale 15.03 251,837 3,785,614 1,492 Nov 24 04:44 PM Hunkapiller Michael Director Nov 20 Sale 15.11 147,799 2,233,538 253,329 Nov 24 04:44 PM Hunkapiller Michael Director Nov 19 Sale 15.55 2,201 34,226 401,128 Nov 20 05:16 PM Hunkapiller Michael Director Nov 18 Sale 15.71 38,381 603,004 403,329 Nov 20 05:16 PM Hunkapiller Michael Director Nov 16 Sale 15.90 42,488 675,347 441,710 Nov 18 04:05 PM Hunkapiller Michael Director Nov 12 Sale 16.73 200,000 3,345,800 484,198 Nov 13 05:17 PM Hunkapiller Michael Director Nov 11 Sale 16.46 250,000 4,116,000 684,198 Nov 13 05:17 PM Hunkapiller Michael Director Nov 11 Sale 14.25 195,652 2,788,041 898,215 Nov 13 05:17 PM Hunkapiller Michael Director Nov 10 Sale 14.25 1,304,348 18,586,959 1,093,867 Nov 13 05:17 PM Hunkapiller Michael CEO & President Aug 25 Sale 6.44 228,632 1,472,619 934,198 Aug 26 05:08 PM MILLIGAN JOHN F Director Aug 24 Option Exercise 3.32 110,000 365,200 110,000 Aug 26 07:29 PM Hunkapiller Michael CEO & President Aug 24 Sale 6.63 259,164 1,719,475 1,162,830 Aug 26 05:08 PM Hunkapiller Michael CEO & President Aug 21 Sale 6.57 189,847 1,246,915 1,421,994 Aug 24 06:04 PM Hunkapiller Michael CEO & President Aug 20 Sale 6.47 256,554 1,659,802 1,611,841 Aug 24 06:04 PM Phillips James Michael SVP, Research & Development Mar 24 Sale 3.05 2,760 8,421 249,220 Mar 24 06:12 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite